Subject to change.
Subject to change.
Keith, a board certified pathologist, joined Roche in 2022 following multiple roles in biotech/biopharma. Keith earned MD/PhD at UCLA, followed by fellowships at Stanford University. He joined industry in 2009, using integrative pathology to enable therapy development as well as improving understanding, diagnosis, and treatment of disease. As part of Global Medical Affairs, he supports DP and multiplex tissue staining projects as a foundation for precision pathology diagnostics of the future.